Profile data is unavailable for this security.
About the company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
- Revenue in USD (TTM)2.69m
- Net income in USD-129.89m
- Incorporated2018
- Employees152.00
- LocationCentury Therapeutics Inc25 N 38TH STREET, 11TH FLOORPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 981-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.centurytx.com/
More ▼
Mergers & acquisitions
| Acquired company | IPSC:NSQ since announced | Transaction value |
|---|---|---|
| Clade Therapeutics Inc | -66.80% | -- |
Data delayed at least 15 minutes, as of Nov 22 2024 19:50 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anixa Biosciences Inc | 0.00 | -12.36m | 98.47m | 4.00 | -- | 4.52 | -- | -- | -0.3906 | -0.3906 | 0.00 | 0.6772 | 0.00 | -- | -- | 0.00 | -50.54 | -59.69 | -52.50 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -42.77m | 98.55m | 47.00 | -- | 4.11 | -- | -- | -0.8066 | -0.8066 | 0.00 | 0.4503 | 0.00 | -- | -- | 0.00 | -50.37 | -48.44 | -54.67 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6859 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Leap Therapeutics Inc | 0.00 | -64.82m | 98.72m | 54.00 | -- | 2.02 | -- | -- | -1.93 | -1.93 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.23 | -80.06 | -106.79 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Fractyl Health Inc | 97.00k | -68.97m | 98.73m | 102.00 | -- | 1.97 | -- | 1,017.84 | -1.43 | -1.43 | 0.002 | 1.05 | 0.0011 | 0.698 | 8.08 | 950.98 | -68.48 | -- | -78.83 | -- | 46.39 | -- | -64,849.48 | -- | 5.57 | -- | 0.376 | -- | -- | -- | -48.15 | -- | -- | -- |
| Immunic Inc | 0.00 | -96.90m | 99.99m | 77.00 | -- | 2.43 | -- | -- | -1.24 | -1.24 | 0.00 | 0.4576 | 0.00 | -- | -- | 0.00 | -147.12 | -72.09 | -213.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Avalo Therapeutics Inc | 820.00k | -8.14m | 100.30m | 19.00 | -- | 4.43 | -- | 122.32 | -10.96 | -10.96 | 0.1976 | 2.35 | 0.0128 | -- | 0.6467 | 43,157.89 | -12.46 | -99.64 | -26.07 | -154.42 | 182.20 | 84.69 | -970.49 | -613.58 | -- | -6.69 | 0.00 | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Coya Therapeutics Inc | 9.55m | -10.70m | 101.58m | 8.00 | -- | 2.89 | -- | 10.63 | -0.6928 | -0.6928 | 0.687 | 2.10 | 0.4027 | -- | -- | 1,194,290.00 | -45.10 | -- | -49.39 | -- | -- | -- | -111.98 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -6.47m | 104.03m | 10.00 | -- | 14.05 | -- | -- | -1.99 | -1.99 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -88.32 | -54.07 | -112.04 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 203.41k | -112.88m | 105.41m | 122.00 | -- | 1.44 | -- | 518.24 | -4.49 | -4.49 | 0.008 | 2.82 | 0.0014 | -- | 0.2184 | 1,667.30 | -75.21 | -59.52 | -96.91 | -71.29 | -- | -- | -55,491.91 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Century Therapeutics Inc | 2.69m | -129.89m | 105.44m | 152.00 | -- | 0.5358 | -- | 39.27 | -1.86 | -1.86 | 0.0372 | 2.31 | 0.0068 | -- | -- | 17,664.47 | -33.04 | -- | -34.83 | -- | -- | -- | -4,837.73 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| INmune Bio Inc | 42.00k | -41.27m | 105.54m | 11.00 | -- | 2.73 | -- | 2,512.88 | -2.18 | -2.18 | 0.0022 | 1.74 | 0.0007 | -- | 0.0228 | 3,818.18 | -71.48 | -37.82 | -94.55 | -41.86 | -- | -- | -98,266.66 | -14,901.03 | -- | -34.08 | 0.0606 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 107.34m | 9.00 | -- | 18.06 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -28.17m | 109.36m | 140.00 | -- | 35.26 | -- | -- | -1.06 | -1.06 | 0.00 | 0.0579 | 0.00 | -- | -- | 0.00 | -96.37 | -- | -165.17 | -- | -- | -- | -- | -- | -- | -16.57 | 0.8306 | -- | -- | -- | -11.06 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -57.45m | 110.26m | 88.00 | -- | 0.6683 | -- | -- | -2.42 | -2.42 | 0.00 | 6.12 | 0.00 | -- | -- | 0.00 | -46.93 | -- | -51.10 | -- | -- | -- | -- | -- | -- | -- | 0.0649 | -- | -- | -- | -31.02 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -30.15m | 112.50m | 5.00 | -- | 1.34 | -- | -- | -0.9117 | -0.9117 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -55.16 | -- | -58.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Century Therapeutics Inc's reporting currency: US Dollar USD
22.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Casdin Capital LLCas of 30 Sep 2024 | 3.21m | 3.79% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.74m | 3.23% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 2.52m | 2.98% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.44m | 2.89% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 2.10m | 2.48% |
| DAFNA Capital Management LLCas of 30 Sep 2024 | 1.70m | 2.01% |
| Adage Capital Management LPas of 30 Sep 2024 | 1.32m | 1.56% |
| Syncona Investment Management Ltd.as of 30 Sep 2024 | 1.21m | 1.43% |
| Geode Capital Management LLCas of 30 Sep 2024 | 968.18k | 1.14% |
| Tang Capital Management LLCas of 30 Sep 2024 | 900.00k | 1.06% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
